Literature DB >> 26975161

Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.

Dawn K Smith, Michelle Van Handel, Richard J Wolitski, Jo Ellen Stryker, H Irene Hall, Joseph Prejean, Linda J Koenig, Linda A Valleroy.   

Abstract

BACKGROUND: In 2014, approximately 40,000 persons in the United States received a diagnosis of human immunodeficiency virus (HIV) infection. Preexposure prophylaxis (PrEP) with daily oral antiretroviral medication is a new, highly effective intervention that could reduce the number of new HIV infections.
METHODS: CDC analyzed nationally representative data to estimate the percentages and numbers of persons in the United States, by transmission risk group, with indications for PrEP consistent with the 2014 U.S. Public Health Service's PrEP clinical practice guideline.
RESULTS: Approximately 24.7% of sexually active adult men who have sex with men (MSM) (492,000 [95% confidence interval {CI} = 212,000-772,000]), 18.5% of persons who inject drugs (115,000 [CI = 45,000-185,000]), and 0.4% of heterosexually active adults (624,000 [CI = 404,000-846,000]), had substantial risks for acquiring HIV consistent with PrEP indications.
CONCLUSIONS: Based on current guidelines, many MSM, persons who inject drugs, and heterosexually active adults have indications for PrEP. A higher percentage of MSM and persons who inject drugs have indications for PrEP than heterosexually active adults, consistent with distribution of new HIV diagnoses across these populations. IMPLICATIONS FOR PUBLIC HEALTH PRACTICE: Clinical organizations, health departments, and community-based organizations should raise awareness of PrEP among persons with substantial risk for acquiring HIV infection and their health care providers. These data can be used to inform scale-up and evaluation of PrEP coverage. Increasing delivery of PrEP and other highly effective HIV prevention services could lower the number of new HIV infections occurring in the United States each year.

Entities:  

Year:  2015        PMID: 26975161

Source DB:  PubMed          Journal:  J Miss State Med Assoc        ISSN: 0026-6396


  17 in total

1.  The Use of Online Posts to Identify Barriers to and Facilitators of HIV Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men: A Comparison to a Systematic Review of the Peer-Reviewed Literature.

Authors:  Alisse Hannaford; Madeleine Lipshie-Williams; Joanna L Starrels; Julia H Arnsten; Jessica Rizzuto; Phillip Cohen; Damon Jacobs; Viraj V Patel
Journal:  AIDS Behav       Date:  2018-04

2.  HIV Pre-Exposure Prophylaxis Implementation Cascade Among Health Care Professionals in the United States: Implications from a Systematic Review and Meta-Analysis.

Authors:  Chen Zhang; James McMahon; Kevin Fiscella; Sarahmona Przybyla; Amy Braksmajer; Natalie LeBlanc; Yu Liu
Journal:  AIDS Patient Care STDS       Date:  2019-12       Impact factor: 5.078

3.  Temporal Trends and Sociodemographic Correlates of PrEP Uptake in Tennessee, 2017.

Authors:  Meredith L Brantley; Peter F Rebeiro; April C Pettit; Allison Sanders; Lyle Cooper; Shanell McGoy; Melissa Morrison
Journal:  AIDS Behav       Date:  2019-10

4.  Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project.

Authors:  Jill Blumenthal; Raphael Landovitz; Sonia Jain; Feng He; Ryan Kofron; Eric Ellorin; Gifty M Ntim; Jamila K Stockman; Katya Corado; K Rivet Amico; David J Moore; Sheldon Morris
Journal:  AIDS Patient Care STDS       Date:  2021-12       Impact factor: 5.944

5.  Brief Report: Informing Strategies to Build PrEP Capacity Among San Francisco Bay Area Clinicians.

Authors:  Oliver Bacon; Rafael Gonzalez; Erin Andrew; Michael B Potter; James R Iñiguez; Stephanie E Cohen; Albert Y Liu; Jonathan D Fuchs
Journal:  J Acquir Immune Defic Syndr       Date:  2017-02-01       Impact factor: 3.731

6.  Estimating the size of HIV-negative MSM population that would benefit from pre-exposure prophylaxis in Florida.

Authors:  Daniel E Mauck; Kristopher P Fennie; Gladys E Ibañez; Eric A Fenkl; Diana M Sheehan; Lorene M Maddox; Emma C Spencer; Mary Jo Trepka
Journal:  Ann Epidemiol       Date:  2020-02-14       Impact factor: 3.797

7.  Multilevel Factors Shaping Awareness of and Attitudes Toward Pre-exposure Prophylaxis for HIV Prevention among Criminal Justice-Involved Women.

Authors:  Emily F Dauria; Andrew Levine; Samantha V Hill; Marina Tolou-Shams; Katerina Christopoulos
Journal:  Arch Sex Behav       Date:  2020-11-24

8.  Brief Report: PrEP Uptake, Adherence, and Discontinuation Among California YMSM Using Geosocial Networking Applications.

Authors:  Ian W Holloway; Ryan Dougherty; Jennifer Gildner; Sean C Beougher; Craig Pulsipher; Jorge A Montoya; Aaron Plant; Arleen Leibowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.771

Review 9.  Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States.

Authors:  Erika Aaron; Cori Blum; Dominika Seidman; Mary Jo Hoyt; Joanne Simone; Meg Sullivan; Dawn K Smith
Journal:  AIDS Patient Care STDS       Date:  2018-01       Impact factor: 5.078

10.  HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.

Authors:  Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Judy Shigenaga; Kimberly A Spaulding; David V Glidden; Megha L Mehrotra; Patricia Defechereux; Monica Gandhi; Robert M Grant; Michael G Shlipak; Vasantha Jotwani
Journal:  AIDS       Date:  2020-04-01       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.